J Clin Neurol.  2007 Sep;3(3):165-167. 10.3988/jcn.2007.3.3.165.

Neurotoxic Syndrome Developed after Taking Sertraline and Risperidone

• Kim JM
• Lee ST
• Song EC
• Jung KH
• Sinn DI
• Chung H
• Chu K
• Kim M

• KMID: 2135498
• DOI: http://doi.org/10.3988/jcn.2007.3.3.165

Abstract

Neuroleptic malignant syndrome and serotonin syndrome share many common clinical features, and the term "Neurotoxic syndrome" can be used when a clear distinction cannot be made between the two. Here we present a case of 19-year-old man who experienced serotonin syndrome caused by sertraline intake, and consecutive neuroleptic malignant syndrome by risperidone. This case suggests that these two syndromes can be concomitantly induced in some patients who are susceptible to these drugs. Clinicians may have to pay close attention to this problem when prescribing drugs to patients who previously showed sensitivity to CNS-acting drugs.

Keyword

Neuroleptics; Serotonin syndrome; Sertraline; Risperidone

MeSH Terms

Antipsychotic Agents
Humans
Neuroleptic Malignant Syndrome
Risperidone*
Serotonin Syndrome
Sertraline*
Young Adult
Antipsychotic Agents
Risperidone
Sertraline

Reference

1. Ananth J, Aduri K, Parameswaran S, Gunatilake S. Neuroleptic malignant syndrome: risk factors, pathophysiology, and treatment. Acta Neuropsychiatrica. 2004. 16:219–228.

2. Caroff SN, Mann SC, Cabrina Campbell E. Neuroleptic malignant syndrome. Adverse Drug React Bull. 2001. 799–802.

3. Mason PJ, Morris VA, BalcezaK TJ. Serotonin syndrome. Presentation of 2 cases and review of the literature. Medicine (Baltimore). 2000. 79:201–209.

4. Boyer EW, Shannon M. The Serotonin Syndrome. N Eng J Med. 2005. 352:1112–1120.

5. Reeves RR, Mack JE, Beddingfield JJ. Neurotoxic Syndrome Associated with Risperidone and Fluvoxamine. Ann Pharmacother. 2002. 36:440–443.

6. Kaufman KR, Levitt MJ, Schiltz JF, Sunderram J. Neuroleptic malignant syndrome and serotonin syndrome in the critical care setting: case analysis. Ann Clin Psychiatry. 2006. 18:201–204.

7. Christensen V, Glenthoj BY. Malignant neuroleptic syndrome or serotonergic syndrome. Ugeskr Laeger. 2001. 163:301–302.

8. Tiryaki A, Kandemir G, Ak I. The life threatening adverse effects of psychotropic drugs: a case report. Turk Psikiyatri Derg. 2006. 17:147–151.

9. Caley CF. Extrapyramidal reactions and the selective serotonin-reuptake inhibitors. Ann Pharmacother. 1997. 31:1481–1489.

10. Kobayashi A, Kawanishi C, Matsumura T, Kato D, Furukawa R, Kishida I, et al. Quetiapine-induced neuroleptic malignant syndrome in dementia with Lewy bodies: a case report. Prog Neuropsychopharmacol Biol Psychiatry. 2006. 30:1170–1172.

11. Mintzner JB, Mullen JA, Aweitzer DE. A comparison of extrapyramidal symptoms in older outpatients treated with quetiapine or risperidone. Curr Med Res Opin. 2004. 20:1483–1491.